-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the marketing application of Sichuan Huiyu Pharmaceutical's Class 4 generic drug Octreotide Acetate Injection has entered the administrative approval stage
.
According to data from Minet.
com, the terminal sales of this product in China's public medical institutions will exceed 2 billion yuan in 2020.
At present, the products of three companies have been reviewed
.
Source: The official website of the State Food and Drug Administration Octreotide acetate is a tetradeceptide human somatostatin analog, its pharmacological action is similar to that of somatostatin, and it can inhibit the pathological secretion of growth hormone (GH) and gastroenteropancreatic (GEP) endocrine system peptides It is clinically suitable for emergency treatment of esophageal-gastric varices bleeding caused by liver cirrhosis, relieving symptoms and signs related to gastroenteropancreatic endocrine tumors, preventing postoperative complications of pancreas,
etc.
At present, 17 domestic pharmaceutical companies have production approvals for octreotide acetate injection.
According to Minet.
com, the product will be available in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals in China in 2020.
The sales volume exceeds 2 billion yuan, of which Novartis dominates the market and has an exclusive market share of over 60%
.
Application of Consistency Evaluation of Octreotide Acetate Injection (including new classification report) Source: Minet.
com Consistency Evaluation Database Three companies, namely Pharma, Sinopharm Yixin Pharmaceutical, and Tianma Pharmaceutical and Tianji Bio, have successfully passed the evaluation; five companies have reported production under the newly registered classification
.
From 2022 to the present, Sichuan Huiyu Pharmaceutical's product dynamics source: Minet.
com MED2.
0 China Drug Evaluation Database Since 2022, Sichuan Huiyu Pharmaceutical has won a new product, which is bortezomib for anti-tumor injection.
This product will be available in 2020 In 2018, the sales volume of terminals in public medical institutions in China exceeded 1.
5 billion yuan.
Octreotide acetate injection is expected to become the second new product won by the company this year
.
Up to now, Sichuan Huiyu Pharmaceutical has 10 injections that have passed or are deemed to have passed the consistency evaluation, among which pemetrexed disodium for injection, docetaxel injection, azacitidine for injection and other blockbuster varieties are the first ones.
Overrated (including tie)
.
.
According to data from Minet.
com, the terminal sales of this product in China's public medical institutions will exceed 2 billion yuan in 2020.
At present, the products of three companies have been reviewed
.
Source: The official website of the State Food and Drug Administration Octreotide acetate is a tetradeceptide human somatostatin analog, its pharmacological action is similar to that of somatostatin, and it can inhibit the pathological secretion of growth hormone (GH) and gastroenteropancreatic (GEP) endocrine system peptides It is clinically suitable for emergency treatment of esophageal-gastric varices bleeding caused by liver cirrhosis, relieving symptoms and signs related to gastroenteropancreatic endocrine tumors, preventing postoperative complications of pancreas,
etc.
At present, 17 domestic pharmaceutical companies have production approvals for octreotide acetate injection.
According to Minet.
com, the product will be available in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals in China in 2020.
The sales volume exceeds 2 billion yuan, of which Novartis dominates the market and has an exclusive market share of over 60%
.
Application of Consistency Evaluation of Octreotide Acetate Injection (including new classification report) Source: Minet.
com Consistency Evaluation Database Three companies, namely Pharma, Sinopharm Yixin Pharmaceutical, and Tianma Pharmaceutical and Tianji Bio, have successfully passed the evaluation; five companies have reported production under the newly registered classification
.
From 2022 to the present, Sichuan Huiyu Pharmaceutical's product dynamics source: Minet.
com MED2.
0 China Drug Evaluation Database Since 2022, Sichuan Huiyu Pharmaceutical has won a new product, which is bortezomib for anti-tumor injection.
This product will be available in 2020 In 2018, the sales volume of terminals in public medical institutions in China exceeded 1.
5 billion yuan.
Octreotide acetate injection is expected to become the second new product won by the company this year
.
Up to now, Sichuan Huiyu Pharmaceutical has 10 injections that have passed or are deemed to have passed the consistency evaluation, among which pemetrexed disodium for injection, docetaxel injection, azacitidine for injection and other blockbuster varieties are the first ones.
Overrated (including tie)
.
